A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506572-27-00

Acronym

CLN-049-002

Enrollment

Registered

2023-11-21

Start date

2024-01-12

Completion date

Unknown

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Spain

None listed

Source: EU CTIS · Data processed: Feb 5, 2026